Beta Bionics Raises 2026 Outlook on Strong Sales, Navigates Patient Growth Dip

IRVINE, CA – April 21, 2026

Beta Bionics, Inc. (Nasdaq: BBNX) delivered a robust first-quarter financial report today, showcasing a 57% surge in year-over-year revenue and prompting an upward revision of its full-year 2026 guidance. The diabetes technology firm's impressive top-line growth, however, was juxtaposed with a sequential slowdown in new patient acquisitions, presenting a complex picture for investors and the market.

Pharmacy Access Strategy Powers Revenue Surge

The primary engine behind the company's stellar performance was its strategic push into the Pharmacy Benefit Plan (PBP) channel. Net sales for the first quarter ended March 31, 2026, reached $27.6 million, a significant leap from $17.6 million in the same period last year. While the traditional Durable Medical Equipment (DME) channel grew a respectable 22% to $16.9 million, the PBP channel's sales skyrocketed by an astounding 181% to $10.7 million.

This shift is a deliberate move by Beta Bionics to make its flagship iLet Bionic Pancreas more accessible. By leveraging pharmacy channels, the company aims to reduce the significant upfront out-of-pocket costs that patients often face with medical devices, while also simplifying the prescription and fulfillment process for healthcare providers. The strategy appears to be paying off, with a "high 30s percentage" of new patient starts in the quarter being reimbursed through the PBP channel, a substantial increase from the "low-20s percentage" a year ago.

This channel optimization has also had a profoundly positive effect on the company's financial health. Gross margin expanded to 59.5%, an increase of 864 basis points from 50.9% in Q1 2025. The growing installed base of users in the pharmacy channel is a key driver of high-margin, recurring revenue from the sale of single-use products, which analysts see as crucial for long-term profitability and user retention.

Buoyed by this success, Beta Bionics raised its full-year 2026 guidance. The company now expects total revenue between $131 million and $136 million, up from a previous estimate of $130 million to $135 million. It also lifted its gross margin forecast to a range of 57.5% to 59.5% and anticipates that 37% to 39% of new patients for the year will come through the PBP channel.

A Paradox in Patient Acquisition

Despite the impressive financial metrics, the report revealed a notable headwind: a sequential decline in new patient starts of between 10% and 20% compared to the fourth quarter of 2025. Company management attributed this dip to typical industry seasonality, where the first quarter often follows a strong year-end push. This was not entirely unexpected, as the company had previously guided for a sequential decline following a strong Q4 2025 that saw 5,592 new patient starts.

A deeper look at the patient acquisition data reveals a more encouraging trend for market expansion. Approximately 70% of new iLet users in the quarter were transitioning from multiple daily injections (MDI), rather than from a competitor's insulin pump. This indicates that Beta Bionics is successfully growing the overall market for automated insulin delivery (AID) systems by reaching a population that has historically been hesitant to adopt pump therapy.

Furthermore, the company continues to see significant organic uptake among individuals with type 2 diabetes, who accounted for 25% to 30% of new patient starts. This is particularly noteworthy as Beta Bionics is currently restricted from actively marketing the iLet system to this population. The strong demand suggests a substantial unmet need and a significant future growth opportunity should the company gain regulatory approval for a broader label.

Positioning Against a Competitive Landscape

Beta Bionics' 57% year-over-year revenue growth is impressive, but it occurs within an intensely competitive and rapidly growing AID market. The global diabetes device market is projected to surpass $37.9 billion by 2026, and major players are also reporting strong results.

Industry giant Medtronic, for example, recently reported 7.9% organic growth in its Diabetes business. Meanwhile, Insulet, maker of the Omnipod system, recently posted first-quarter revenue growth of 31.2% year-over-year, beating expectations. Tandem Diabetes Care, another key competitor, is also expected to report its quarterly earnings in the coming weeks after a strong finish to 2025.

In this environment, Beta Bionics is differentiating itself not just through its unique "bionic pancreas" algorithm, which automates nearly all insulin dosing decisions, but also through its channel strategy. The aggressive and successful expansion into the PBP channel may provide a crucial competitive advantage in accessibility and affordability, helping it capture new market share from the large MDI population.

Innovating for the Future of Diabetes Care

Looking beyond the quarterly numbers, Beta Bionics highlighted significant progress in its innovation pipeline, signaling its long-term vision for diabetes management. In March, the company launched Bionic Insights™, a new data analytics feature for its healthcare provider portal. This tool is designed to translate complex glucose data into actionable clinical recommendations, helping clinicians personalize treatment and improve patient outcomes. Early feedback from providers has been described as "overwhelmingly positive," suggesting the feature addresses a critical need to simplify data interpretation.

Perhaps most significantly, the company has initiated a Phase 2a feasibility trial in New Zealand for its next-generation bihormonal system. This system, which includes a glucagon asset alongside insulin, aims to more closely mimic a healthy pancreas by delivering both hormones to regulate blood sugar. A successful bihormonal system could offer superior glucose control and dramatically reduce the risk of dangerous low blood sugar (hypoglycemia), representing a major leap forward from current insulin-only systems.

These research and development efforts, which contributed to an increase in operating expenses to $40.7 million, underscore the company's commitment to pushing the boundaries of diabetes technology. While the path to commercializing a bihormonal system is long and subject to rigorous regulatory review, the start of this trial marks a critical milestone in the company's journey to redefine automated diabetes care.

The combination of a strong financial quarter, a successful and expanding pharmacy channel strategy, and a forward-looking R&D pipeline positions Beta Bionics as a dynamic player in the evolving landscape of diabetes technology.